Celltrion’s Biosimilar Rituximab Edges Ahead With Korean Approval
Executive Summary
Celltrion has edged ahead of its competitors in the close race to develop biosimilar versions of rituximab with the approval of its product in South Korea, which could help speed development in other markets where the South Korean firm is also seeking approvals.